NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy
VERAXA Biotech has started cell line development for its lead BiTAC T-cell engager program in collaboration with ATUM, aiming to improve tumor selectivity and reduce off-tumor toxicity. This move follows encouraging preclinical data and supports advancement toward clinical development.
VERAXA announced the initiation of cell line development for its lead BiTAC T-cell engager program through a collaboration with ATUM.
ATUM will apply its Leap-In Transposase technology to generate stable clonal cell lines.
The cell lines will support IND/CTA-enabling activities, future clinical development, CMC development (including early process, analytical, and formulation development), and production of material for nonclinical studies.
The BiTAC platform splits the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell, creating a conditional 'AND'-gated approach.
It is designed to reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.
Encouraging preclinical data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
The full press release is available at https://ibn.fm/FCIlk.
VERAXA aims to build a premier engine for discovering and developing next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats.